GET DAILY SIGNALSErasca (ERAS) Q3 2026 Earnings: Pipeline Progress and Cash Runway in Focus
Key Takeaways
- Erasca is a clinical-stage precision oncology company with no product revenue, so third-quarter results will center on spending discipline and clinical milestones rather than sales.
- Wall Street consensus calls for a net loss of roughly $0.13 per share for the quarter ended September 30, 2026, versus a $0.11 loss in the same period a year earlier.
- In its most recent quarter (Q2 2026), Erasca reported a $0.14 per-share loss, missing the $0.11 consensus estimate; investors will watch whether that trajectory improves.
- Cash burn and the company's runway will be closely scrutinized after January's $225 million and July's upsized $550 million financing rounds.
- Updates on lead candidate ERAS-0015 (a pan-RAS molecular glue) and ERAS-4001 (a pan-KRAS inhibitor) could move the stock more than the headline loss figure.
- For more on ERAS, including Major News, Today's Price Move, Price Targets, and Forecasts, explore the dedicated pages for deeper insight.
- Investors seeking additional market signals can also explore Trending AI Robots for automated trading ideas.
Earnings Context and Why It Matters
Erasca is a clinical-stage precision oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Because the company has no approved products, it generates no revenue, meaning its quarterly report is less about sales and more about how efficiently it is funding drug development. The third-quarter update arrives at a pivotal moment, shortly after two large capital raises and encouraging early data for its lead program. From what I see, the report offers a window into whether management can advance its pipeline toward registrational trials while preserving a cash runway currently projected into the second half of 2028. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect Erasca to report a net loss of approximately $0.13 per share for the third quarter of 2026, a modest improvement from the $0.14 loss reported in the prior quarter and slightly wider than the $0.11 loss in the year-ago period. Consensus estimates have been largely stable over the past two months, reflecting steady expectations around the company's clinical strategy. Given Erasca's pre-revenue status, no meaningful revenue figure is anticipated; the focus instead falls on operating expenses, research and development (R&D) costs, and cash consumption. The company has beaten consensus EPS in four of its last eight quarters, but its most recent report missed, underscoring the difficulty of forecasting a development-stage biotech's quarterly spend.
Market Reaction and Investor Sentiment
Heading into the report, sentiment around ERAS remains constructive despite ongoing losses. Seven of nine analysts rate the stock a "Buy," with an average price target near $24, well above recent trading levels. The stock has climbed sharply from its 52-week low of $2.21, though it still trades below its 52-week high of $24.28. Sentiment has been shaped less by the earnings line than by pipeline news, including July's disclosure of Phase 1 data showing tumor responses for ERAS-0015 across multiple cancer types and plans for three registrational trials in pancreatic and lung cancers. Key risks include a wider-than-expected loss, accelerating cash burn, or any sign that clinical timelines are slipping. One thing that stands out to me is how pipeline updates often outweigh the actual earnings number in these situations.
Forward Outlook and Key Factors to Monitor
Beyond the headline loss, investors will focus on how quickly Erasca is deploying its recently raised capital. After January's $225 million raise and July's upsized $550 million financing, the company has said its cash position should fund operations into the second half of 2028. Any commentary on cash runway, R&D spending, or hiring will signal whether management is keeping costs aligned with its clinical milestones.
The most important catalyst remains ERAS-0015, the pan-RAS molecular glue being studied in the AURORAS-1 Phase 1 trial. Management plans to advance it into registrational studies in pancreatic and lung cancers, so updates on trial design, enrollment, or regulatory feedback could materially affect the stock.
Equally significant is ERAS-4001, a pan-KRAS inhibitor, with initial Phase 1 monotherapy data previously guided for the second half of 2026. Confirmation that this timeline remains on track would be a notable positive. Because Erasca is still years from potential product revenue, investors should monitor spending efficiency, data milestones, and any shifts in guidance rather than short-term profitability. I’m watching this closely as the data readouts approach.
Exploring Tickeron’s AI Tools for Biotech Analysis
In my own research process, I often turn to Tickeron’s suite of AI-driven platforms to cross-check clinical-stage names like this one. The AI Screener helps filter for similar oncology plays based on patterns and fundamentals, while the AI Trend Prediction Engine offers another lens on potential momentum. These tools have become a regular part of how I evaluate pre-revenue companies ahead of key updates, saving time without replacing careful fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ERAS in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
ERAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 31 cases where ERAS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ERAS as a result. In 77 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ERAS just turned positive on November 09, 2026. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in 45 of 56 cases over the following month. The odds of a continued upward trend are 80%.
ERAS moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +17.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in 209 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for ERAS moved below the 200-day moving average on November 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ERAS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.928) is normal, around the industry mean (3.498). P/E Ratio (-15.168) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement